| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444726 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
Although no significant difference in OS was observed in this study, extensive crossover from placebo to pazopanib confounded final OS analysis. Post-hoc analyses adjusting for crossover suggest OS benefit with pazopanib treatment for mRCC patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Cora N. Sternberg, Robert E. Hawkins, John Wagstaff, Pamela Salman, Jozef Mardiak, Carlos H. Barrios, Juan J. Zarba, Oleg A. Gladkov, Eunsik Lee, Cezary Szczylik, Lauren McCann, Stephen D. Rubin, Mei Chen, Ian D. Davis,